PTEN和Survivin在膀胱尿路上皮癌中的表达及相互关系
|
摘要
目的：研究肿瘤抑制基因PTEN和凋亡抑制基因Survivin在膀胱尿路上皮癌中的蛋白表达情况,探讨二者与膀胱尿路上皮癌的分级、分期及预后的相关性和临床意义。
方法：应用免疫组织化学SP染色方法检测60例膀胱尿路上皮癌及10例正常膀胱粘膜组织中PTEN蛋白和Survivin蛋白的表达。采用SPSS13.0软件包进行统计学分析。
结果：(1)PTEN蛋白在10例正常膀胱组织中均有广泛黄染,均呈阳性表达,8例着色于细胞核,2例着色于细胞质。在60例膀胱尿路上皮癌组织中有21例阳性表达。PTEN蛋白在膀胱尿路上皮癌中的表达与在正常膀胱粘膜中的表达比较差异有明显统计学意义(P<0.01)。PTEN蛋白在膀胱尿路上皮癌的低级别与高级别、非浸润性与浸润性、初发与复发之间等各组之间表达差异有统计学意义(P<0.05)。在单发与多发、无淋巴结转移和有淋巴结转移之间表达差异无统计学意义(P>0.05)。PTEN蛋白阳性表达率与膀胱尿路上皮癌组织的分级、分期和肿瘤复发呈负相关显著性差异。(2)Survivin蛋白在10例正常膀胱组织中呈阴性表达。在60例膀胱尿路上皮癌组织中有42例Survivin蛋白着色于细胞核。Survivin蛋白在膀胱尿路上皮癌中的表达与在正常膀胱粘膜中的表达比较差异有明显统计学意义(P<0.01)。Survivin蛋白在膀胱尿路上皮癌组织的低级别与高级别、非浸润性与浸润性、单发与多发、初发与复发等各组之间表达差异均有统计学意义(P<0.05)。在无淋巴结转移和有淋巴结转移之间表达差异无统计学意义(P>0.05)。Survivin蛋白的阳性表达率与膀胱尿路上皮癌组织的分级、分期、肿瘤数量和肿瘤复发呈正相关显著性差异。(3)PTEN蛋白在膀胱尿路上皮癌的阴性表达与同时存在的Survivin蛋白阳性表达之间有明显统计学意义(P<0.01)。呈明显负相关显著性差异。
结论：PTEN蛋白在膀胱尿路上皮癌和正常膀胱组织的阳性表达呈明显负相关,Survivin蛋白则呈明显正相关。PTEN和Survivin蛋白的表达与膀胱尿路上皮癌的生物学行为关系密切,可协同参与膀胱癌的生物学行为。PTEN蛋白的阳性表达与膀胱尿路上皮癌的恶性程度、分期及预后大致呈负相关,Survivin蛋白在膀胱尿路上皮癌中异常表达具有普遍性,其阳性表达与膀胱尿路上皮癌的恶性程度、分期及预后大致呈正相关。PTEN和Survivin蛋白的阳性表达在膀胱尿路上皮癌中呈明显负相关。联合检测PTEN和Survivin蛋白对诊断膀胱尿路上皮癌、判断其恶性程度及预后有一定参考价值。
Objective:To investigate the protein expression and interrelation between the tumor suppress gene PTEN and apoptosis suppress gene Survivin in bladder urothelial carcinoma as well as to investigate the relationship and clinic significance of PTEN, Survivin in grade, stage and prognosis in bladder urothelial carcinoma.
Methods:The expression of PTEN and Survivin protein were detected by S-P immunohistochemistry technique in 60 cases of bladder urothelial carcinoma and 10 cases of normal bladder mucosa. statistics analysis was progress with SPSS13.0 package.
Results:(1) All 10 cases normal bladder tissues had positive express-ion of PTEN.8 cases colored caryon and 3 cases colored cytoplasm.21 positive expression in 60 cases bladder urothelial carcinoma. There was obviously statistically significantly differences of PTEN protein positive between bladder urothelial carcinoma and nomal bladder tissues (P<0.01). There was statistical significance in lower grade and higher grade, non-invasive and invasive, primary and recurrent cases(P<0.05). There was no statistical significance in single occurrence and multi-occurrence, non-lymphoid node metastasis and lymphoid node metastasis cases(P>0.05). The higher the grade, stage and recurrent of tumor was,the lower the expression of PTEN protein. (2) All 10 cases normal bladder tissues had not positive expression of Survivin protein.42 cases Survivin protein colored caryon in 60 cases bladder urothelial carcinoma. There was obviously statistically significantly differences of Survivin protein positive between bladder urothelial carcinoma and nomal bladder tissues(P<0.01).There was statistical significance in lower grade and higher grade, non-invasive and invasive, single occurrence and multi-occurrence, primary and recurrent cases (P<0.05). There was no statistical significance in non-lymphoid node metastasis and lymphoid node metastasis cases(P>0.05). The higher the grade,stage,quantity, and recurrent of tumor was,the higher the expression of Survivin. (3) There was obviously statistically significantly differences between PTEN protein negative expression and simultaneous Survivin protein positive expression in bladder urothelial carcinoma (P<0.01).
Conclusion:The positive expression of the PTEN protein was a obviously negative correlation between in urothelial carcinoma of the bladder and in normal bladder tissues.The close relationship was found between the abnormal expression of PTEN, Survivin protein and the behavior in biology of the urothelial carcinoma of the bladder. PTEN and Survivin had the synergism.There was a negative correlation between the positive expression of the PTEN protein and malignancy degree, stage and prognosis of urothelial carcinoma of the bladder. The abnormal expression of Survivin is common in urothelial carcinoma of the bladder and there was a positive correlation between the positive expression of the Survivin protein and malignancy degree, stage and prognosis of urothelial carcinoma of the bladder.The expression of PTEN and Survivin protein presented significantly negative correlation.The coexpression of survivin and PTEN had invariably reference value in diagnosis, malignant degree and prognosis in urothelial carcinoma of the bladder.
方法：应用免疫组织化学SP染色方法检测60例膀胱尿路上皮癌及10例正常膀胱粘膜组织中PTEN蛋白和Survivin蛋白的表达。采用SPSS13.0软件包进行统计学分析。
结果：(1)PTEN蛋白在10例正常膀胱组织中均有广泛黄染,均呈阳性表达,8例着色于细胞核,2例着色于细胞质。在60例膀胱尿路上皮癌组织中有21例阳性表达。PTEN蛋白在膀胱尿路上皮癌中的表达与在正常膀胱粘膜中的表达比较差异有明显统计学意义(P<0.01)。PTEN蛋白在膀胱尿路上皮癌的低级别与高级别、非浸润性与浸润性、初发与复发之间等各组之间表达差异有统计学意义(P<0.05)。在单发与多发、无淋巴结转移和有淋巴结转移之间表达差异无统计学意义(P>0.05)。PTEN蛋白阳性表达率与膀胱尿路上皮癌组织的分级、分期和肿瘤复发呈负相关显著性差异。(2)Survivin蛋白在10例正常膀胱组织中呈阴性表达。在60例膀胱尿路上皮癌组织中有42例Survivin蛋白着色于细胞核。Survivin蛋白在膀胱尿路上皮癌中的表达与在正常膀胱粘膜中的表达比较差异有明显统计学意义(P<0.01)。Survivin蛋白在膀胱尿路上皮癌组织的低级别与高级别、非浸润性与浸润性、单发与多发、初发与复发等各组之间表达差异均有统计学意义(P<0.05)。在无淋巴结转移和有淋巴结转移之间表达差异无统计学意义(P>0.05)。Survivin蛋白的阳性表达率与膀胱尿路上皮癌组织的分级、分期、肿瘤数量和肿瘤复发呈正相关显著性差异。(3)PTEN蛋白在膀胱尿路上皮癌的阴性表达与同时存在的Survivin蛋白阳性表达之间有明显统计学意义(P<0.01)。呈明显负相关显著性差异。
结论：PTEN蛋白在膀胱尿路上皮癌和正常膀胱组织的阳性表达呈明显负相关,Survivin蛋白则呈明显正相关。PTEN和Survivin蛋白的表达与膀胱尿路上皮癌的生物学行为关系密切,可协同参与膀胱癌的生物学行为。PTEN蛋白的阳性表达与膀胱尿路上皮癌的恶性程度、分期及预后大致呈负相关,Survivin蛋白在膀胱尿路上皮癌中异常表达具有普遍性,其阳性表达与膀胱尿路上皮癌的恶性程度、分期及预后大致呈正相关。PTEN和Survivin蛋白的阳性表达在膀胱尿路上皮癌中呈明显负相关。联合检测PTEN和Survivin蛋白对诊断膀胱尿路上皮癌、判断其恶性程度及预后有一定参考价值。
Objective:To investigate the protein expression and interrelation between the tumor suppress gene PTEN and apoptosis suppress gene Survivin in bladder urothelial carcinoma as well as to investigate the relationship and clinic significance of PTEN, Survivin in grade, stage and prognosis in bladder urothelial carcinoma.
Methods:The expression of PTEN and Survivin protein were detected by S-P immunohistochemistry technique in 60 cases of bladder urothelial carcinoma and 10 cases of normal bladder mucosa. statistics analysis was progress with SPSS13.0 package.
Results:(1) All 10 cases normal bladder tissues had positive express-ion of PTEN.8 cases colored caryon and 3 cases colored cytoplasm.21 positive expression in 60 cases bladder urothelial carcinoma. There was obviously statistically significantly differences of PTEN protein positive between bladder urothelial carcinoma and nomal bladder tissues (P<0.01). There was statistical significance in lower grade and higher grade, non-invasive and invasive, primary and recurrent cases(P<0.05). There was no statistical significance in single occurrence and multi-occurrence, non-lymphoid node metastasis and lymphoid node metastasis cases(P>0.05). The higher the grade, stage and recurrent of tumor was,the lower the expression of PTEN protein. (2) All 10 cases normal bladder tissues had not positive expression of Survivin protein.42 cases Survivin protein colored caryon in 60 cases bladder urothelial carcinoma. There was obviously statistically significantly differences of Survivin protein positive between bladder urothelial carcinoma and nomal bladder tissues(P<0.01).There was statistical significance in lower grade and higher grade, non-invasive and invasive, single occurrence and multi-occurrence, primary and recurrent cases (P<0.05). There was no statistical significance in non-lymphoid node metastasis and lymphoid node metastasis cases(P>0.05). The higher the grade,stage,quantity, and recurrent of tumor was,the higher the expression of Survivin. (3) There was obviously statistically significantly differences between PTEN protein negative expression and simultaneous Survivin protein positive expression in bladder urothelial carcinoma (P<0.01).
Conclusion:The positive expression of the PTEN protein was a obviously negative correlation between in urothelial carcinoma of the bladder and in normal bladder tissues.The close relationship was found between the abnormal expression of PTEN, Survivin protein and the behavior in biology of the urothelial carcinoma of the bladder. PTEN and Survivin had the synergism.There was a negative correlation between the positive expression of the PTEN protein and malignancy degree, stage and prognosis of urothelial carcinoma of the bladder. The abnormal expression of Survivin is common in urothelial carcinoma of the bladder and there was a positive correlation between the positive expression of the Survivin protein and malignancy degree, stage and prognosis of urothelial carcinoma of the bladder.The expression of PTEN and Survivin protein presented significantly negative correlation.The coexpression of survivin and PTEN had invariably reference value in diagnosis, malignant degree and prognosis in urothelial carcinoma of the bladder.
引文
1. Li J, Yen C, Liaw D, et al.PTEN,a putative protein tyrosine phosphatas.gene mutated in human brain, breast,and prostate cancer.Science,1997,275(5308): 1943-1947
2. Lee J,Yang H,Georgescu MM,et al.Crystal structure of the PTEN tumor suppressor:implications for its phosphoinositide phosphatase activity and membrane association. Cell,1999,99 (3):323-334
3. Weng L,Brown J,Eng C.PTEN induced apoptosis and cell cycle arrest through phosphoinsi to 123 kinase pak dependent and independem pathways. mum Mol Genet,2001,10(3):237-242
4. Huang J,Kontos CD.PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects[J].J Biol chem.,2002,277(13):10760-10766
5. Abe T,Terada K,Wakimoto H,et al.PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli [J].Cancer Research,2003, 63(9):2300-2305
6. Stambolic V,Tsao MS, Macpherson D, et al. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in PTEN+/- mice [J]. Cancer Res,2000,60 (13):3605
7.钟义洋,王健.Her-2、PTEN蛋白在膀胱癌中的表达及意义[J].青海医学院学报,2007,28：175-178
8. Tsuruta H,Kishimoto H,Sasaki T,et al.Hyperplasia and Carcinomas in Pten-Deficient Mice and Reduced PTEN Protein in Human Bladder Cancer Patients. Caner Res,2006,66(17):8389-8396
9. Aveyard JS.Somatic mutation of PTEN in bladder carcinoma [J].Br J Cancer, 1999,80(5-6):904-908
10.张建华,杨为民,周四维等.PTEN和VEGF的表达与膀胱癌血管生成关系的研究[J].中华泌尿外科杂志,2005,26：598-600
11.Oconnor D S,Schechner J S, Adida C, et al. Control of apoptosis during an-giogenesis by survivin expression in endothelial cells[J].Am J Pathol,2000,156 (6):393-398
12. Papapetropoulos A, Fulton D,Mahboubi K, et al.Angiopoietin-1 inhibits end-othelial cell apoptosis via the Akt/survivin pathway[J]. Biol Chem,2000,275 (13): 9102-9105
13. Swana H S, Grossman D, Anthony J N, et al. Tuor content of the antiapoptosis molecule survivin and recurrence of bladder cancer[J].N Engl J Med,1999, 341:452-453
14. Ku J H, Kwak C, Lee H S, et al. Expression of Survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder[J].Urol, 2004,171(2pt 1):631-635
15. Smith S D,Wheeler M A, Plescia J, et al. Urine detection of Survivin and diagnosis of bladder cancer[J]. JAMA,2001,285(3):324-328
16.汪良,曾甫清,廖贵益等.检测膀胱癌患者尿液脱落细胞中Survivin的表达及意义[J].临床泌尿外科杂志,2004,19(8)：489-490
17. Keesee K,Briggman JV,Thill G,et al.Utilization of unclear matrix proteins for cancer diagnosis [J].Crit Rev Eukaryot Gene Expr,1996,6(2-3)1:189-214
18.Zippe C,Pandrangi L,A garwal A.NMP22 is sensitive, cost-effective test in patients at risk for bladder cancer[J].J Urol,1999,161(1):62-65
19. Sanchez-Carbayo M, Herrero E, Megias J, et al.Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder[J].BJU Int,1999,84(6):706-713
20. Sozen S, Biri H, Sinik Z, et al.Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder[J]. Eur Urol,1999,36(3):225-229
21. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care protemic assay[J].JAMA,2005,16(7):810-816
22. Shariat SF, Casella R, Uiams FH, et al. Risk stratification for bladder tumor recurrence, stage and grade by urinary nulear matrix protein 22 and cytology[J]. Eur Urol,2004,45(3):304-313
23.Kibar Y, Goktas S, Kilic S, et al. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II(UGC Ⅱ) test in early recurrent transitional cell carcinoma of the bladder[J].Ann Clin Lab Sci,2006, 36(1):31-38
24. Kim NW.Specific association of human telomerase activity with immortal cells and cancer. Science,1994,266:2011-2015
25.彭钧铮,张元芳,丁强等.膀胱癌组织中端粒酶活性研究[J].中华泌尿外科杂志,1997,18(10)：601-603
26. Hess J L.Telomerase detection in body fluids[J].Clin Chem,2002,48(1):18-24
27. Rothacker J,Ramsay RG, Ciznadija D, et al.A novel magneticbead-based assay with high sensitivity and selectivity for analysis of telomerase in exfoliated cells from patients with bladder and colon eancer. Electrophoresis,2007,28 (23): 4435-4446
28. D Hallewin M A,Baert L.lnital evaluation of bladder tumor antigen teatin supertieial bladder cancer[J].J Urol,1996,155(2):475
29. Glas AS,Roos D,Deutekom M,et al.Tumor markers in the diagnosis of primary bladder cancer:a systematic review[J].J Urol,2003,169:1975-1982
30. Raitanen MP,The FinnBladder Group.The role of BTA stat Test in Follow-up of patients with bladder cancer:results from FinnBladder studies.World J Urol,2008, 26(1):45-50
31. Pode D,hapiro A,Wald M,et al.J Urol,1999,16(2):443-446
32. Krupski T,Moskalukc,et al.BJU Int,2000,85(9):1027-1032
33. Irani J,Desgrandchamps F,et al.Eur Uuol,1999,35(2):85-92
34. Liu Ningfei,Gao Feng,Han zeqiu,et al.Hyaluronan synthase 3 expression p romotes the growth of TSU prostate cancer cells[J].Cancer Res,2001,61(13):5207-5214
35. Itano N,Atsumi F.sawai T,et al.Abnormal accumulation of hyalufonan Matrix diminishes contact inhibition of cell growth and promotes cell migraion[J]. Proc Natl Acad Sci USA,2002,99(6):3609-3614
36. Guler G,Sarac S,Uner A, et al.Prognostic value of CD44 variant 6 in Laryngeal epidermoid carcinomas[J].Arch Otolaryngol Head Neck Surg,2002,128 (4): 393-397
37.岳培彬.膀胱癌生物标志物的研究进展[J].国外医学.临床生物与检验学分册,2002,23(1)：34-35
38. Schroeder GL, Lorenzo Comez MF, Hautmann SH, et al. A side by comparison of cytology and biomarkers for bladder cancer detection[J].J Urol,2004,172(3): 1123-1126
1. Fearon ER, Feinberg AP, Hamiton SH, et al. Loss of genes on the short arm of chromosome 11 in bladder cancer.Nature,1985,318:377-380
2. Li J,Yen C,Lian D,et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [J]. Science,1997,275:1943-1947
3. Steck PA, Pershouse MA, Jasser SA, et al.Identification of a candidate tumor suppressor gene,MMA C1,at chromosome 10q23.3 that is mutated in multiple advanced cancers[J].Nat Genet,1997,15:356-362
4. Li DM, Sun H.TEP1,encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor β[J]. Cancer Res,1997,57:2124-2129
5.田新霞,吴浩强.新的肿瘤抑制基因PTEN[J].中华病理学杂志,2000,29：455-457
6.周隽,吴强.肿瘤抑制基因PTEN的研究进展[J].癌变、畸变、突变,200214：131-134
7. Ambrosini G, A did a C, Altieri D C.A novel anti-apoptosis gene, surviving, express ed in cancer and lymphoma[J].Nat Med,1997,3(8):917-921
8.陈国庭,尹浩然,朱正刚.PTEN基因的研究进展[J].国外医学遗传学分册,2001,24：71-73
9. Hu TH, Huang CC, lin PR, et al.Expression and prognostic role of tumor suppres sor gene PTEN/MMAC1/TEP1 in hepatoculluar carcinoma[J].Cancer,2003,97 (8): 1929.
10. Horie Y, Suzuki A,Kataoka E, et al.Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas[J].J Clin Invest,2004,113(12): 1774
11. Steck PA, et al.Identification of a candidate tumour suppressor gene, MMACI, at chromosome 10q23.3 that is mutated in multiple advanced cancers[J].Nat Genet, 1997,15(4):356-362
12.Besson A, Robbins SM, et al.PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis [J].Eur J Biochem,1999,263(3):605
13. Giri D, Ittmann M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma[J]. Hum Pathol,1999,30(4):419-424
14. McMenamin ME, et al.Loss of PTEN expression in paraffinembedded primary prostate cancer correlates with high Gleason score and advanced stage[J]. Cancer Res,1999,59(17):4291-4296
15.Tanaka M, Koul D, Davies MA, et al. MMACI/PTEN inhibits cell growth and induceschemo sensitivity to doxorubicin in human bladder cancer cells[J]. Oncogene,2000,19(47):5406-5412
16. Aveyard JS, Skilleter A, Habuchi T, et al. Somatic mutation of PTEN in bladder carcinoma [J].Br J Cancer,1999,80(5-6):904-908
17. GINN PEASE ME.Increased nuclear phosphatase and tensinhomologue delcted on chromosome 10 is associated with Go2G1 in MCF27 cells[J].Cancer Res,2003, 63(2):282-286
18. Tamura M, Gu J, Matsumoto K, et al. Inhibition of cell migration, spreading,and focal adhesions by tumor suppressor PTEN[J].Science,1998,280(5369):1614-1617
19. Koul D, Shen R, Garyali A, et al.MMAC/PTEN tumor suppressor gene regulates vascular endothelial factormediated angiogenesis in prostate cancer. Int J Oncol,2002,21:469-475
20. Li X P, Huang W X, Song M Z. Advance in PTEN suppressor oncogen. Tumor Journal of World,2003,2:66-69
21.Kanamori Y, Kigawa J, Itamoehi H.PTEN expression is associated with p-rognosis for patients with advanced endometrial carcinoma undergoing post-operative chemotherapy. Int J Cancer,2002,100:686-689
22.Dohi T, Okada K, Xia F, et al.An IAP-IAP complex inhibits apoptosis[J].J iol Chem,2004,279 (33):34087-34090
23. Verdecia M A, Huang H, Dutil E, et al.Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement[J].Nat Struct Biol,2000,7(7):602-608
24. Lehner R, Lucia M S, Elke A, et al. Immunohistochemical localization of the AP protein survivin in bladder mucoss and transitional cell carcinoma[J]. Appl Immunohlstochem Mol Morphol,2002,10(2):134-138
25. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, caspases and anticancer drugs [J].Cancer Res,1998,58(23):5315-5320
26. Miller M, Smith D, Windsor A, et al. Survivin gene expression and prognosis in recurrent colorectal cancer[J].Gut,2001,48(1):137-138
27. Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25,is significantly associated with poor prognostic factors cell survival in human neuroblastoma [J].Oncogene,2000,19(5):617-623
28. Swana H S, Grossman D, Anthony J N, et al. Tuor content of the antiapoptosis molecule survivin and recurrence of bladder cancer[J].N Engl J Med,1999,341: 452-453
29. Waston JAM. Necrosis and apoptosis in the gastrointestinal tract [J].Gut,1995, 3(2):165
30. Bao R, Connolly DC, Murphy M, et al. Activation of cancer gene specificgene expression by the survivin promoter[J].J Nat1 Cancer Inst,2002,94(7):522
31.Sarela AI, Macadam RC, Farmery SM, et al. Expression of the antiapoptosis gene,surviving, predicls death from recurrent colorectal carcinoma[J].Gut,2000, 6(5):645-650
32. Suzuki A, Hayashiha M, Ito T, et al. Survivin initiates cell cycleentry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/CyclinE complex activation[J].Oncogene,2000,19(29):3225-3234
2. Lee J,Yang H,Georgescu MM,et al.Crystal structure of the PTEN tumor suppressor:implications for its phosphoinositide phosphatase activity and membrane association. Cell,1999,99 (3):323-334
3. Weng L,Brown J,Eng C.PTEN induced apoptosis and cell cycle arrest through phosphoinsi to 123 kinase pak dependent and independem pathways. mum Mol Genet,2001,10(3):237-242
4. Huang J,Kontos CD.PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects[J].J Biol chem.,2002,277(13):10760-10766
5. Abe T,Terada K,Wakimoto H,et al.PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli [J].Cancer Research,2003, 63(9):2300-2305
6. Stambolic V,Tsao MS, Macpherson D, et al. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in PTEN+/- mice [J]. Cancer Res,2000,60 (13):3605
7.钟义洋,王健.Her-2、PTEN蛋白在膀胱癌中的表达及意义[J].青海医学院学报,2007,28：175-178
8. Tsuruta H,Kishimoto H,Sasaki T,et al.Hyperplasia and Carcinomas in Pten-Deficient Mice and Reduced PTEN Protein in Human Bladder Cancer Patients. Caner Res,2006,66(17):8389-8396
9. Aveyard JS.Somatic mutation of PTEN in bladder carcinoma [J].Br J Cancer, 1999,80(5-6):904-908
10.张建华,杨为民,周四维等.PTEN和VEGF的表达与膀胱癌血管生成关系的研究[J].中华泌尿外科杂志,2005,26：598-600
11.Oconnor D S,Schechner J S, Adida C, et al. Control of apoptosis during an-giogenesis by survivin expression in endothelial cells[J].Am J Pathol,2000,156 (6):393-398
12. Papapetropoulos A, Fulton D,Mahboubi K, et al.Angiopoietin-1 inhibits end-othelial cell apoptosis via the Akt/survivin pathway[J]. Biol Chem,2000,275 (13): 9102-9105
13. Swana H S, Grossman D, Anthony J N, et al. Tuor content of the antiapoptosis molecule survivin and recurrence of bladder cancer[J].N Engl J Med,1999, 341:452-453
14. Ku J H, Kwak C, Lee H S, et al. Expression of Survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder[J].Urol, 2004,171(2pt 1):631-635
15. Smith S D,Wheeler M A, Plescia J, et al. Urine detection of Survivin and diagnosis of bladder cancer[J]. JAMA,2001,285(3):324-328
16.汪良,曾甫清,廖贵益等.检测膀胱癌患者尿液脱落细胞中Survivin的表达及意义[J].临床泌尿外科杂志,2004,19(8)：489-490
17. Keesee K,Briggman JV,Thill G,et al.Utilization of unclear matrix proteins for cancer diagnosis [J].Crit Rev Eukaryot Gene Expr,1996,6(2-3)1:189-214
18.Zippe C,Pandrangi L,A garwal A.NMP22 is sensitive, cost-effective test in patients at risk for bladder cancer[J].J Urol,1999,161(1):62-65
19. Sanchez-Carbayo M, Herrero E, Megias J, et al.Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder[J].BJU Int,1999,84(6):706-713
20. Sozen S, Biri H, Sinik Z, et al.Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder[J]. Eur Urol,1999,36(3):225-229
21. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care protemic assay[J].JAMA,2005,16(7):810-816
22. Shariat SF, Casella R, Uiams FH, et al. Risk stratification for bladder tumor recurrence, stage and grade by urinary nulear matrix protein 22 and cytology[J]. Eur Urol,2004,45(3):304-313
23.Kibar Y, Goktas S, Kilic S, et al. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II(UGC Ⅱ) test in early recurrent transitional cell carcinoma of the bladder[J].Ann Clin Lab Sci,2006, 36(1):31-38
24. Kim NW.Specific association of human telomerase activity with immortal cells and cancer. Science,1994,266:2011-2015
25.彭钧铮,张元芳,丁强等.膀胱癌组织中端粒酶活性研究[J].中华泌尿外科杂志,1997,18(10)：601-603
26. Hess J L.Telomerase detection in body fluids[J].Clin Chem,2002,48(1):18-24
27. Rothacker J,Ramsay RG, Ciznadija D, et al.A novel magneticbead-based assay with high sensitivity and selectivity for analysis of telomerase in exfoliated cells from patients with bladder and colon eancer. Electrophoresis,2007,28 (23): 4435-4446
28. D Hallewin M A,Baert L.lnital evaluation of bladder tumor antigen teatin supertieial bladder cancer[J].J Urol,1996,155(2):475
29. Glas AS,Roos D,Deutekom M,et al.Tumor markers in the diagnosis of primary bladder cancer:a systematic review[J].J Urol,2003,169:1975-1982
30. Raitanen MP,The FinnBladder Group.The role of BTA stat Test in Follow-up of patients with bladder cancer:results from FinnBladder studies.World J Urol,2008, 26(1):45-50
31. Pode D,hapiro A,Wald M,et al.J Urol,1999,16(2):443-446
32. Krupski T,Moskalukc,et al.BJU Int,2000,85(9):1027-1032
33. Irani J,Desgrandchamps F,et al.Eur Uuol,1999,35(2):85-92
34. Liu Ningfei,Gao Feng,Han zeqiu,et al.Hyaluronan synthase 3 expression p romotes the growth of TSU prostate cancer cells[J].Cancer Res,2001,61(13):5207-5214
35. Itano N,Atsumi F.sawai T,et al.Abnormal accumulation of hyalufonan Matrix diminishes contact inhibition of cell growth and promotes cell migraion[J]. Proc Natl Acad Sci USA,2002,99(6):3609-3614
36. Guler G,Sarac S,Uner A, et al.Prognostic value of CD44 variant 6 in Laryngeal epidermoid carcinomas[J].Arch Otolaryngol Head Neck Surg,2002,128 (4): 393-397
37.岳培彬.膀胱癌生物标志物的研究进展[J].国外医学.临床生物与检验学分册,2002,23(1)：34-35
38. Schroeder GL, Lorenzo Comez MF, Hautmann SH, et al. A side by comparison of cytology and biomarkers for bladder cancer detection[J].J Urol,2004,172(3): 1123-1126
1. Fearon ER, Feinberg AP, Hamiton SH, et al. Loss of genes on the short arm of chromosome 11 in bladder cancer.Nature,1985,318:377-380
2. Li J,Yen C,Lian D,et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [J]. Science,1997,275:1943-1947
3. Steck PA, Pershouse MA, Jasser SA, et al.Identification of a candidate tumor suppressor gene,MMA C1,at chromosome 10q23.3 that is mutated in multiple advanced cancers[J].Nat Genet,1997,15:356-362
4. Li DM, Sun H.TEP1,encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor β[J]. Cancer Res,1997,57:2124-2129
5.田新霞,吴浩强.新的肿瘤抑制基因PTEN[J].中华病理学杂志,2000,29：455-457
6.周隽,吴强.肿瘤抑制基因PTEN的研究进展[J].癌变、畸变、突变,200214：131-134
7. Ambrosini G, A did a C, Altieri D C.A novel anti-apoptosis gene, surviving, express ed in cancer and lymphoma[J].Nat Med,1997,3(8):917-921
8.陈国庭,尹浩然,朱正刚.PTEN基因的研究进展[J].国外医学遗传学分册,2001,24：71-73
9. Hu TH, Huang CC, lin PR, et al.Expression and prognostic role of tumor suppres sor gene PTEN/MMAC1/TEP1 in hepatoculluar carcinoma[J].Cancer,2003,97 (8): 1929.
10. Horie Y, Suzuki A,Kataoka E, et al.Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas[J].J Clin Invest,2004,113(12): 1774
11. Steck PA, et al.Identification of a candidate tumour suppressor gene, MMACI, at chromosome 10q23.3 that is mutated in multiple advanced cancers[J].Nat Genet, 1997,15(4):356-362
12.Besson A, Robbins SM, et al.PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis [J].Eur J Biochem,1999,263(3):605
13. Giri D, Ittmann M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma[J]. Hum Pathol,1999,30(4):419-424
14. McMenamin ME, et al.Loss of PTEN expression in paraffinembedded primary prostate cancer correlates with high Gleason score and advanced stage[J]. Cancer Res,1999,59(17):4291-4296
15.Tanaka M, Koul D, Davies MA, et al. MMACI/PTEN inhibits cell growth and induceschemo sensitivity to doxorubicin in human bladder cancer cells[J]. Oncogene,2000,19(47):5406-5412
16. Aveyard JS, Skilleter A, Habuchi T, et al. Somatic mutation of PTEN in bladder carcinoma [J].Br J Cancer,1999,80(5-6):904-908
17. GINN PEASE ME.Increased nuclear phosphatase and tensinhomologue delcted on chromosome 10 is associated with Go2G1 in MCF27 cells[J].Cancer Res,2003, 63(2):282-286
18. Tamura M, Gu J, Matsumoto K, et al. Inhibition of cell migration, spreading,and focal adhesions by tumor suppressor PTEN[J].Science,1998,280(5369):1614-1617
19. Koul D, Shen R, Garyali A, et al.MMAC/PTEN tumor suppressor gene regulates vascular endothelial factormediated angiogenesis in prostate cancer. Int J Oncol,2002,21:469-475
20. Li X P, Huang W X, Song M Z. Advance in PTEN suppressor oncogen. Tumor Journal of World,2003,2:66-69
21.Kanamori Y, Kigawa J, Itamoehi H.PTEN expression is associated with p-rognosis for patients with advanced endometrial carcinoma undergoing post-operative chemotherapy. Int J Cancer,2002,100:686-689
22.Dohi T, Okada K, Xia F, et al.An IAP-IAP complex inhibits apoptosis[J].J iol Chem,2004,279 (33):34087-34090
23. Verdecia M A, Huang H, Dutil E, et al.Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement[J].Nat Struct Biol,2000,7(7):602-608
24. Lehner R, Lucia M S, Elke A, et al. Immunohistochemical localization of the AP protein survivin in bladder mucoss and transitional cell carcinoma[J]. Appl Immunohlstochem Mol Morphol,2002,10(2):134-138
25. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, caspases and anticancer drugs [J].Cancer Res,1998,58(23):5315-5320
26. Miller M, Smith D, Windsor A, et al. Survivin gene expression and prognosis in recurrent colorectal cancer[J].Gut,2001,48(1):137-138
27. Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25,is significantly associated with poor prognostic factors cell survival in human neuroblastoma [J].Oncogene,2000,19(5):617-623
28. Swana H S, Grossman D, Anthony J N, et al. Tuor content of the antiapoptosis molecule survivin and recurrence of bladder cancer[J].N Engl J Med,1999,341: 452-453
29. Waston JAM. Necrosis and apoptosis in the gastrointestinal tract [J].Gut,1995, 3(2):165
30. Bao R, Connolly DC, Murphy M, et al. Activation of cancer gene specificgene expression by the survivin promoter[J].J Nat1 Cancer Inst,2002,94(7):522
31.Sarela AI, Macadam RC, Farmery SM, et al. Expression of the antiapoptosis gene,surviving, predicls death from recurrent colorectal carcinoma[J].Gut,2000, 6(5):645-650
32. Suzuki A, Hayashiha M, Ito T, et al. Survivin initiates cell cycleentry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/CyclinE complex activation[J].Oncogene,2000,19(29):3225-3234